If you’ve seen the viral social media stories about “Ozempic babies,” you might wonder: Does Ozempic^® affect fertility? The sudden wave of pregnancies among those on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has surprised patients and doctors alike. But the relationship between GLP-1 medications and fertility is more nuanced than headlines suggest. 

To understand how medications like Ozempic^® can affect fertility, it helps understand how these drugs work. GLP-1 RAs (like Ozempic^® and Wegovy^®) and dual GLP-1/GIP RAs (like Mounjaro^® and Zepbound^®) mimic natural gut hormones. They regulate blood sugar, slow digestion, and tell your brain you’re full. While clinical guidelines approve GLP-1 RAs primarily to treat type 2 diabetes or manage chronic weight, these metabolic shifts can restore ovulation. Whether you’re actively trying to conceive or working to avoid it, these changes require intentional planning.

This article breaks down how GLP-1 RAs interact with your reproductive system. We'll cover how these medications alter ovulation, why they can interfere with oral birth control, and what to do if you discover you’re pregnant while taking them.

How can GLP-1 medications affect fertility?

GLP-1 RAs aren’t fertility treatments. However, the significant weight loss and metabolic improvements they produce can remove the barriers keeping your body from ovulating. This is especially true if you have polyendocrine metabolic ovarian syndrome (PMOS, formerly known as PCOS) or if extra weight has disrupted your hormonal balance.

Here’s how that process works.

Fat loss lowers estrogen levels

Fat cells contain an enzyme called aromatase, which turns other hormones into estrogen. Carrying extra fat tissue causes your body to produce more estrogen than it needs. This tells your brain you’ve already ovulated. As a result, your brain stops sending follicle-stimulating hormone (FSH), which your ovaries need to mature and release eggs. As weight drops during GLP-1 treatment, estrogen levels rebalance. This allows your brain to resume normal FSH signaling to get your eggs back on track.

Insulin sensitivity improves and androgen levels fall

Chronic metabolic strain can cause insulin resistance, a hallmark of PMOS. Your cells ignore insulin, forcing your pancreas to overproduce it. This flood of excess insulin travels to your ovaries, telling them to produce too much androgen. This male hormone halts egg maturation and release. 

Because GLP-1 RAs improve how your body processes sugar, they restore insulin sensitivity to normal levels. This brings insulin and androgen levels down, allowing your body to restart regular ovulatory cycles.

Overall metabolic health improves

GLP-1 medications regulate blood sugar and lower inflammation, acting as a safety signal to your reproductive system. When you’re in a state of high metabolic stress, your body often lowers reproductive function to focus on survival. By easing that stress and lowering ovulation interference from insulin, these medications restore a stable baseline. This tells your body it’s safe to support a pregnancy.

What does the research say about GLP-1s and PMOS (PCOS) fertility?

Much of what we know about the connection between GLP-1 RAs and fertility comes from data involving individuals with PMOS. In this condition, insulin resistance, high androgen levels, and irregular ovulation frequently overlap. Here’s what the research says.

Data on natural conception rates

A 2023 meta-analysis shows that for those with PCOS, GLP-1 RAs can increase the likelihood of natural conception by up to 72%. The medications do this by easing metabolic stress, which restores regular ovulation. While this leads to more spontaneous pregnancies, studies haven’t shown the same increase in success for those undergoing in vitro fertilization (IVF). Because IVF involves using hormones to override your natural cycle, the boost from GLP-1 RAs is less impactful.

Limitations of older drug formulations

Most trials in this review studied older GLP-1 formulations like liraglutide and exenatide. While effective, these medications are generally less potent than the newer drugs like semaglutide or tirzepatide. It’s possible that these newer formulations could increase natural conception even further. However, we’re still waiting for long-term studies to confirm this.

Clues from animal studies and ovarian cells

A 2025 review found that in animal studies, GLP-1 RAs sometimes corrected ovarian cycle problems and reduced ovarian follicle cysts. Furthermore, recent laboratory research identified GLP-1 receptors directly inside human and animal ovarian cells. This suggests GLP-1 medications may affect the ovaries more than experts previously thought. However, research remains in its early stages.

What you should know about contraception while on a GLP-1

Can you get pregnant on Ozempic^® or another GLP-1 medication? Yes, and the medication can actually make it more likely. Ovulation can return before your first period does, so you may be fertile before you even realize it. If pregnancy isn’t in your plans right now, here’s what to consider about contraception while on a GLP-1 RA treatment.

Tirzepatide slows absorption of contraception

Tirzepatide (Foundayo^®) significantly slows the speed at which your stomach empties into your intestines. Because oral birth control pills rely on consistent absorption in the intestinal tract, this delay can cut contraception’s effectiveness by 55–66%. It can also lower your overall hormone exposure by about 20–23%. This weakening effect peaks after your first dose of tirzepatide and following each dose increase. 

Semaglutide doesn’t slow absorption of contraception

In contrast, semaglutide (Ozempic^®) doesn’t alter the absorption of oral medications to any clinically relevant degree. A dedicated study in the Journal of Clinical Pharmacology confirmed this specifically for birth control pills.

Gastrointestinal (GI) side effects can affect absorption of contraception

Both semaglutide and tirzepatide cause GI side effects like vomiting and diarrhea. Because oral birth control relies on your digestive tract for absorption, these side effects can interfere with its effectiveness:

• If you vomit within two to three hours of taking your birth control pill, your body likely didn’t absorb enough of the hormones. Treat this as a missed dose, and follow your prescription’s missed-dose instructions. 
• If you have severe diarrhea lasting more than 24 hours, continue taking your pills on a regular schedule. Use backup contraception like condoms while you’re ill and for up to seven days after symptoms resolve.

Why providers might recommend non-oral contraception

The FDA recommends adding a barrier method like condoms for four weeks after starting a GLP-1 medication or increasing your dose. For more reliable protection, providers may suggest switching to non-oral contraceptives. These can include intrauterine devices (IUDs), contraceptive implants, or rings. Non-oral methods bypass your digestive system entirely, remaining effective regardless of side effects.

When to stop GLP-1 before pregnancy

If you’re trying to conceive, ask your doctor about your timeline:

• Semaglutide (Ozempic^® and Wegovy^®): The FDA recommends stopping the medication at least two months before a planned pregnancy. Semaglutide stays active in your body for about a week after each dose and takes roughly five weeks to clear your system completely. 
• Tirzepatide (Mounjaro^® and Zepbound^®): Your body eliminates the drug completely after around 25 days. The FDA label doesn’t specify a preconception washout period; it only instructs to stop if you become pregnant. Work closely with your healthcare provider to establish a personalized timeline based on your health history.

If you discover you’re pregnant while taking GLP-1 medication, stop taking the drug immediately, and contact your provider. Current data remains too limited to definitively confirm or rule out fetal risks, so discontinuation is the safest first step. Both Novo Nordisk (manufacturer of Wegovy^® and Ozempic^®) and Eli Lilly (manufacturer of Zepbound^® and Mounjaro^®) maintain active pregnancy exposure registries to track maternal and fetal outcomes. Your provider can help you enroll if appropriate. 

Planning your fertility journey with Maven Clinic

GLP-1 RA treatments can improve your weight and baseline metabolic health, making pregnancy possible if you previously struggled to conceive. However, managing these medications alongside family planning requires careful coordination across multiple healthcare providers. 

Maven Clinic brings these separate conversations together in a single space. You gain direct access to experts who understand how GLP-1 RA treatment interacts with your reproductive health. This means you never have to piece together conflicting guidance from isolated clinics on your own.

Connect with Maven Clinic today to align your GLP-1 care with your family-building goals.

FAQ

Does Ozempic® affect fertility?

Ozempic® (semaglutide) isn’t a fertility treatment. But the weight loss and metabolic changes it produces can restart ovulation in women who weren’t ovulating regularly, including those with PMOS. Emerging research has found GLP-1 receptors in ovarian cells, suggesting these medications could influence egg development more directly. But scientists don’t yet know how much that matters in practice.

Can tirzepatide boost fertility?

Like semaglutide, tirzepatide (Mounjaro®, Zepbound®) isn’t a fertility treatment. But the metabolic changes it produces may support ovulation and fertility in some women. It’s also important to know that tirzepatide also reduces how much of an oral birth control pill the body absorbs, which may cause some women to become pregnant unexpectedly. 

Can tirzepatide decrease the effectiveness of oral birth control pills?

Yes. FDA data shows that a single dose of tirzepatide cuts peak blood level of the hormones in birth control pills by 55–66%. Delayed digestion that slows pill absorption causes this effect. The FDA recommends switching to a non-oral method (like an IUD or implant) or adding a barrier method for four weeks after starting tirzepatide and after each dose increase.